Braveheart Bio priced an upsized $382.5 million IPO to advance its oral cardiac myosin inhibitor BHB-1893 into Phase 3 development for obstructive and non-obstructive hypertrophic cardiomyopathy. The company will begin global Phase 3 studies in oHCM later in 2026, while non-obstructive trials are slated to start in early 2027. The asset was acquired from Hengrui Pharmaceuticals in a licensing deal that included up to $1 billion, highlighting how China-sourced late-stage assets continue to anchor new U.S. IPO narratives. Braveheart’s offering included a 30-day underwriter option to add more shares, and the proceeds are earmarked for the pivotal trial program. Separately, this broader market moment is reinforced by another large public-market entry: Attovia’s $289 million IPO for immunology and inflammation drugs, extending the biotech IPO streak into multiple concurrent listings this week.